Paroxetine Hydrochloride side effects: what 41,070 FDA adverse event reports show
Drug class
Not stated in label
Who reports
41,070 reports · 84% serious · 5,352 with death outcome · 64% female
Used for
Major Depressive Disorder Paroxetine tablets, USP are indicated for the treatment of major depressive disorder. The efficacy of paroxetine in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ).
What it is
DESCRIPTION Paroxetine tablets, USP are an orally administered psychotropic drug. It is the hydrochloride salt of a phenylpiperidine compound identified chemically as (-)-trans-4R-(4'-fluoroph.
Boxed warning
Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,176 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Self mutilation | 97 | 167.4 128.8–217.5ROR 167.5 · calibrated p 3e-9 ✓ | 95.1 EB05 80.3 · IC025 +5.7 3/3 methods agree | Not in label — unassessed | – | no trial arm names this drug |
| Congenital aortic stenosis | 85 | 164.1 124.1–216.8ROR 164.2 · calibrated p 4e-9 ✓ | 93.8 EB05 78.2 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | – | no trial arm names this drug |
| Fallot's tetralogy | 117 | 115.9 92.7–144.7ROR 116.0 · calibrated p 5e-8 ✓ | 76.2 EB05 65.3 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | – | no trial arm names this drug |
| Persistent foetal circulation | 199 | 110.3 93.1–130.6ROR 110.5 · calibrated p 6e-8 ✓ | 74.1 EB05 65.9 · IC025 +5.7 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=33 · ♀ 0% (drug 64%) | no trial arm names this drug |
| Pulmonary artery stenosis congenital | 193 | 82.5 70.0–97.2ROR 82.6 · calibrated p 5e-7 ✓ | 60.5 EB05 53.6 · IC025 +5.5 3/3 methods agree | Labeled (related wording) related wording | – | no trial arm names this drug |
| Bicuspid aortic valve | 155 | 81.7 68.0–98.2ROR 81.9 · calibrated p 6e-7 ✓ | 60.0 EB05 52.5 · IC025 +5.4 3/3 methods agree | Not in label — unassessed | – | no trial arm names this drug |
| Myoglobin urine present | 65 | 81.3 61.3–108.0ROR 81.4 · calibrated p 8e-7 ✓ | 59.2 EB05 48.1 · IC025 +5.0 3/3 methods agree | Lab value / disease marker | serious n=60 · ♀ 100% (drug 64%) · 100% clinician | no trial arm names this drug |
| Pulmonary valve stenosis | 208 | 80.8 69.0–94.7ROR 81.0 · calibrated p 6e-7 ✓ | 59.6 EB05 53.1 · IC025 +5.5 3/3 methods agree | Not in label — unassessed | serious n=31 · 100% clinician | no trial arm names this drug |
| Coarctation of the aorta | 200 | 59.8 51.2–69.8ROR 59.9 · calibrated p 5e-6 ✓ | 47.4 EB05 42.1 · IC025 +5.2 3/3 methods agree | Not in label — unassessed | 100% clinician | no trial arm names this drug |
| Pulmonary valve stenosis congenital | 88 | 57.6 45.6–72.8ROR 57.6 · calibrated p 7e-6 ✓ | 45.7 EB05 38.3 · IC025 +4.8 3/3 methods agree | Labeled (related wording) related wording | – | no trial arm names this drug |
| Activation syndrome | 69 | 56.9 43.7–74.1ROR 57.0 · calibrated p 8e-6 ✓ | 45.2 EB05 36.9 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | – | no trial arm names this drug |
| Transposition of the great vessels | 143 | 50.9 42.5–61.0ROR 51.0 · calibrated p 1e-5 ✓ | 41.6 EB05 36.2 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | – | no trial arm names this drug |
| Patent ductus arteriosus | 713 | 50.3 46.4–54.6ROR 50.7 · calibrated p 1e-5 ✓ | 41.4 EB05 38.9 · IC025 +5.2 3/3 methods agree | Not in label — unassessed | serious n=96 | no trial arm names this drug |
| Hypoplastic left heart syndrome | 111 | 45.7 37.3–56.0ROR 45.8 · calibrated p 3e-5 ✓ | 38.0 EB05 32.4 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | – | no trial arm names this drug |
| Heart disease congenital | 555 | 42.6 38.9–46.6ROR 42.8 · calibrated p 4e-5 ✓ | 36.0 EB05 33.5 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious n=55 · ♀ 0% (drug 64%) | no trial arm names this drug |
| Atrial septal defect | 1,299 | 42.3 39.9–44.9ROR 42.9 · calibrated p 3e-5 ✓ | 35.8 EB05 34.2 · IC025 +5.1 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 8.7 | no trial arm names this drug |
| Congenital anomaly | 1,198 | 42.0 39.5–44.6ROR 42.5 · calibrated p 4e-5 ✓ | 35.6 EB05 33.9 · IC025 +5.0 3/3 methods agree | Labeled (related wording) related wording | serious PRR 4.2 · ♀ 44% (drug 64%) | no trial arm names this drug |
| Craniosynostosis | 131 | 41.0 34.0–49.4ROR 41.0 · calibrated p 5e-5 ✓ | 34.7 EB05 30.0 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | – | no trial arm names this drug |
| Ventricular septal defect | 855 | 40.3 37.5–43.3ROR 40.7 · calibrated p 5e-5 ✓ | 34.4 EB05 32.5 · IC025 +5.0 3/3 methods agree | Labeled adverse reaction exact term | serious n=137 · ♀ 32% (drug 64%) | no trial arm names this drug |
| Multiple congenital abnormalities | 213 | 39.7 34.3–45.9ROR 39.8 · calibrated p 6e-5 ✓ | 33.8 EB05 30.2 · IC025 +4.8 3/3 methods agree | Labeled (related wording) related wording | serious n=33 | no trial arm names this drug |
| Electric shock | 122 | 38.9 32.1–47.1ROR 38.9 · calibrated p 7e-5 ✓ | 33.2 EB05 28.5 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | – | no trial arm names this drug |
| Congenital hydrocephalus | 71 | 37.2 28.9–47.8ROR 37.2 · calibrated p 1e-4 ✓ | 31.9 EB05 26.1 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=40 · 100% clinician | no trial arm names this drug |
| Talipes | 399 | 34.0 30.7–37.8ROR 34.2 · calibrated p 1e-4 ✓ | 29.7 EB05 27.3 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious n=59 · ♀ 0% (drug 64%) | no trial arm names this drug |
| Cogwheel rigidity | 120 | 29.7 24.6–35.9ROR 29.7 · calibrated p 3e-4 ✓ | 26.3 EB05 22.6 · IC025 +4.3 3/3 methods agree | Labeled adverse reaction exact term | serious n=114 | no trial arm names this drug |
| Depersonalisation | 89 | 27.2 21.8–33.9ROR 27.2 · calibrated p 5e-4 ✓ | 24.3 EB05 20.3 · IC025 +4.1 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | 100% clinician | no trial arm names this drug |
| Agoraphobia | 134 | 25.1 21.0–30.0ROR 25.1 · calibrated p 7e-4 ✓ | 22.6 EB05 19.6 · IC025 +4.1 3/3 methods agree | Likely indication confounding term in indications | serious n=77 | no trial arm names this drug |
| Congenital cardiovascular anomaly | 81 | 24.3 19.4–30.6ROR 24.4 · calibrated p 9e-4 ✓ | 22.0 EB05 18.2 · IC025 +3.9 3/3 methods agree | Labeled (related wording) related wording | – | no trial arm names this drug |
| Limb malformation | 75 | 23.8 18.8–30.2ROR 23.8 · calibrated p 1e-3 ✓ | 21.6 EB05 17.8 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | – | no trial arm names this drug |
| Drug exposure during pregnancy | 3,193 | 23.6 22.7–24.4ROR 24.4 · calibrated p 8e-4 ✓ | 21.5 EB05 20.8 · IC025 +4.4 3/3 methods agree | Reporting / coding artifact | serious PRR 2.9 | no trial arm names this drug |
| Cardiac murmur | 791 | 23.1 21.5–24.9ROR 23.3 · calibrated p 1e-3 ✓ | 21.1 EB05 19.9 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious PRR 4.1 | no trial arm names this drug |
| Granuloma skin | 74 | 22.7 17.8–28.8ROR 22.7 · calibrated p 0.001 ✓ | 20.6 EB05 16.9 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=71 · ♀ 100% (drug 64%) · 100% clinician | no trial arm names this drug |
| Right ventricular hypertrophy | 80 | 22.2 17.7–28.0ROR 22.3 · calibrated p 0.001 ✓ | 20.3 EB05 16.8 · IC025 +3.8 3/3 methods agree | Labeled (related wording) related wording | – | no trial arm names this drug |
| Cleft palate | 155 | 20.1 17.1–23.7ROR 20.1 · calibrated p 0.002 ✓ | 18.5 EB05 16.2 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | – | no trial arm names this drug |
| Arnold-chiari malformation | 75 | 19.6 15.5–24.8ROR 19.6 · calibrated p 0.002 ✓ | 18.0 EB05 14.8 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | – | no trial arm names this drug |
| Autism | 79 | 19.2 15.3–24.2ROR 19.2 · calibrated p 0.003 ✓ | 17.7 EB05 14.7 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | – | no trial arm names this drug |
| Serotonin syndrome | 1,456 | 19.0 18.0–20.1ROR 19.3 · calibrated p 0.002 ✓ | 17.6 EB05 16.9 · IC025 +4.0 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 25.7 · serious PRR 20.6 | no trial arm names this drug |
| Derealisation | 161 | 18.8 16.0–22.1ROR 18.8 · calibrated p 0.003 ✓ | 17.4 EB05 15.3 · IC025 +3.8 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=119 | no trial arm names this drug |
| Homicide | 134 | 18.5 15.5–22.1ROR 18.5 · calibrated p 0.003 ✓ | 17.2 EB05 14.8 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=75 · ♀ 33% (drug 64%) | no trial arm names this drug |
| Cleft lip and palate | 81 | 17.9 14.2–22.4ROR 17.9 · calibrated p 0.004 ✓ | 16.6 EB05 13.7 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | – | no trial arm names this drug |
| Anticholinergic syndrome | 112 | 17.5 14.4–21.2ROR 17.5 · calibrated p 0.004 ✓ | 16.2 EB05 13.9 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=109 · ♀ 0% (drug 64%) | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Suicidality | 3,561 | 7.57.3–7.7 | signal |
| Hyponatraemia | 910 | 5.85.5–6.2 | signal |
| Extrapyramidal | 1,090 | 5.35.0–5.6 | signal |
| Rhabdomyolysis / myopathy | 573 | 3.63.3–3.9 | signal |
| Depression | 1,895 | 3.53.3–3.6 | signal |
| Dependence / withdrawal | 1,717 | 3.02.8–3.1 | signal |
| Fall / fracture | 1,697 | 2.32.2–2.4 | signal |
| Liver injury | 1,216 | 2.12.0–2.2 | raised |
| Arrhythmia / qt | 758 | 2.01.9–2.1 | raised |
| Interstitial lung disease | 366 | 2.01.8–2.2 | raised |
| Kidney injury | 1,708 | 1.91.8–2.0 | raised |
| Seizure | 702 | 1.81.7–2.0 | raised |
| Severe cutaneous reaction | 262 | 1.81.6–2.0 | raised |
| Gi bleeding | 562 | 1.61.4–1.7 | raised |
| Pancreatitis | 242 | 1.51.4–1.7 | raised |
| Anaemia | 806 | 1.41.3–1.5 | raised |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug withdrawal syndrome | 6,206 | 17.4 16.9–17.8ROR 18.6 · calibrated p 0.003 ✓ | 16.2 EB05 15.9 · IC025 +4.0 3/3 methods agree | Labeled (related wording) related wording | age-adj. PRR 7.5 · serious PRR 4.0 | no trial arm names this drug |
| Drug ineffective (drug did not work) | 6,171 | 1.1 1.1–1.1ROR 1.1 · calibrated p 0.368 | 1.1 EB05 1.1 · IC025 +0.1 | Reporting / coding artifact | age-adj. PRR 1.1 · serious PRR 1.3 | no trial arm names this drug |
| Nausea | 6,068 | 1.8 1.7–1.8ROR 1.8 · calibrated p 0.857 | 1.8 EB05 1.7 · IC025 +0.8 | Likely indication confounding term in indications; also in warnings | age-adj. PRR 1.2 · serious PRR 1.6 | no trial arm names this drug |
| Dizziness | 5,416 | 2.5 2.5–2.6ROR 2.6 · calibrated p 0.757 | 2.5 EB05 2.5 · IC025 +1.3 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 1.5 · serious PRR 1.8 | no trial arm names this drug |
| Anxiety | 5,379 | 4.4 4.3–4.6ROR 4.7 · calibrated p 0.276 | 4.4 EB05 4.3 · IC025 +2.1 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 3.3 · serious PRR 3.2 | no trial arm names this drug |
| Fatigue (tiredness) | 5,374 | 1.6 1.6–1.7ROR 1.6 · calibrated p 0.736 | 1.6 EB05 1.6 · IC025 +0.6 | Likely indication confounding term in indications | age-adj. PRR 1.3 · serious PRR 1.6 | no trial arm names this drug |
| Headache | 4,761 | 1.8 1.7–1.8ROR 1.8 · calibrated p 0.836 | 1.8 EB05 1.7 · IC025 +0.8 | Labeled adverse reaction exact term | age-adj. PRR 1.4 · serious PRR 1.8 | no trial arm names this drug |
| Depression | 4,308 | 4.4 4.3–4.6ROR 4.6 · calibrated p 0.282 | 4.4 EB05 4.3 · IC025 +2.1 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 3.1 · serious PRR 3.0 | no trial arm names this drug |
| Diarrhoea (diarrhea) | 3,901 | 1.4 1.4–1.5ROR 1.4 · calibrated p 0.593 | 1.4 EB05 1.4 · IC025 +0.4 | Labeled adverse reaction exact term | age-adj. PRR 1.3 · serious PRR 1.5 | no trial arm names this drug |
| Insomnia (trouble sleeping) | 3,827 | 3.4 3.3–3.5ROR 3.5 · calibrated p 0.494 | 3.3 EB05 3.2 · IC025 +1.7 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.4 · serious PRR 2.9 | no trial arm names this drug |
| Vomiting | 3,278 | 1.6 1.6–1.7ROR 1.6 · calibrated p 0.737 | 1.6 EB05 1.6 · IC025 +0.6 | Labeled adverse reaction exact term | age-adj. PRR 1.5 · serious PRR 1.5 | no trial arm names this drug |
| Suicidal ideation (thoughts of suicide) | 3,230 | 8.4 8.1–8.7ROR 8.7 · calibrated p 0.051 | 8.2 EB05 7.9 · IC025 +3.0 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 7.0 · serious PRR 5.3 | no trial arm names this drug |
| Drug exposure during pregnancy | 3,193 | 23.6 22.7–24.4ROR 24.4 · calibrated p 8e-4 ✓ | 21.5 EB05 20.8 · IC025 +4.4 3/3 methods agree | Reporting / coding artifact | serious PRR 2.9 | no trial arm names this drug |
| Weight increased (weight gain) | 3,162 | 3.3 3.2–3.4ROR 3.4 · calibrated p 0.508 | 3.3 EB05 3.2 · IC025 +1.7 3/3 methods agree | Labeled (related wording) related wording | age-adj. PRR 2.3 · serious PRR 2.9 | no trial arm names this drug |
| Pain | 3,141 | 1.2 1.1–1.2ROR 1.2 · calibrated p 0.434 | 1.2 EB05 1.1 · IC025 +0.2 | Likely indication confounding term in indications; also in warnings | age-adj. PRR 1.2 · serious PRR 1.1 | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Self mutilation — n=97, PRR 167.4
- Congenital aortic stenosis — n=85, PRR 164.1
- Fallot's tetralogy — n=117, PRR 115.9
- Bicuspid aortic valve — n=155, PRR 81.7
- Pulmonary valve stenosis — n=208, PRR 80.8
- Coarctation of the aorta — n=200, PRR 59.8
- Activation syndrome — n=69, PRR 56.9
- Transposition of the great vessels — n=143, PRR 50.9
- Patent ductus arteriosus — n=713, PRR 50.3
- Hypoplastic left heart syndrome — n=111, PRR 45.7
✓ A hand-written Bradford Hill causality assessment exists for this drug: Paroxetine (SSRIs) ↔ Discontinuation (withdrawal) syndrome.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Paroxetine?
In FDA FAERS, the most frequently co-reported reaction terms for Paroxetine are drug withdrawal syndrome, nausea, dizziness, anxiety, fatigue, headache. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Paroxetine have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders.
Do FAERS signals prove that Paroxetine causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 0a8a58c7-5008-4c65-ae0e-e4ee809b1807, effective 20220902; matched on
openfda.generic_name.exact:"PAROXETINE" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,216 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
PAROXETINE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.